LITU HOLDINGS (01008) announces profit growth: It is expected that the company's owner's share of profit in 2024 will be approximately HK$66 million to HK$100 million, turning from loss to profit.
Striving Holdings (01008) announced that the group expects the profit attributable to owners of the company in 2024 to be approximately HK$ 66 to 100 million.
LITU HOLDINGS (01008) announced that the group is expected to have a net profit attributable to owners of the company of approximately HK$66 million to HK$100 million in 2024, while the net loss attributable to owners of the company was approximately HK$163.9 million in 2023.
The announcement stated that the turnaround from a net loss to a net profit for owners of the company was mainly due to a decrease in impairment losses on investments in associates of approximately HK$66.4 million, a decrease in impairment losses on goodwill of approximately HK$92.7 million, and an increase in the group's gross profit, primarily attributed to the implementation of new cost control measures.
Related Articles
HK Stock Market Move | JINGCHENG MAC (00187) increased by over 5%, affiliated with Beijing Bawei to support the world's first tower-type solar thermal replacement project for ultra-heavy oil extraction being put into operation.
Innovative drug blockbuster! Arvinas (ARVN.US) collaborates with Pfizer Inc. (PFE.US) to advance the third-party commercialization of "breast cancer ER degrader."
BOCOM INTL: Slight differences between domestic and foreign capital in the industry fluctuations, seizing the opportunity to layout the undervalued high-quality assets in the innovative pharmaceutical industry chain.
HK Stock Market Move | JINGCHENG MAC (00187) increased by over 5%, affiliated with Beijing Bawei to support the world's first tower-type solar thermal replacement project for ultra-heavy oil extraction being put into operation.
Innovative drug blockbuster! Arvinas (ARVN.US) collaborates with Pfizer Inc. (PFE.US) to advance the third-party commercialization of "breast cancer ER degrader."
BOCOM INTL: Slight differences between domestic and foreign capital in the industry fluctuations, seizing the opportunity to layout the undervalued high-quality assets in the innovative pharmaceutical industry chain.
